Objective The objective of the study is to assess the structural and functional cardiac
effects of treatment with losartan in patients with hypertrophic cardiomyopathy (HCM).
Design The study is a randomized, placebo‐controlled, double‐blinded trial. The follow‐up
period is 12 months. 130 patients with HCM will be included in predefined subgroups. Genotype
positive relatives with borderline hypertrophy (> 13 mm) will also be included. Data on
individuals with borderline hypertrophy will be analysed separately from the rest of the
Primary outcome Ventricular hypertrophy assessed as left ventricular mass and maximal wall